Brief: FDA Grants IND Approval For Phase 2 Clinical Trial Of Innovation Pharmaceuticals’ Brilacidin To Treat COVID-19
21/12/2020 12:12
Dec 21 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK :
* FDA GRANTS IND APPROVAL FOR PHASE 2 CLINICAL TRIAL OF
INNOVATION
PHARMACEUTICALS’ BRILACIDIN FOR TREATING COVID-19
* INNOVATION PHARMACEUTICALS - PHASE 2 CLINICAL TRIAL
EXPECTED TO
ENROLL ABOUT 120 PATIENTS WITH MODERATE-TO-SEVERE COVID-19
Source text for Eikon: ID:nGNX9vtf9P
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review